The effect of monotherapy and combined therapy with NSC-631570 (Ukrain) on growth of low- and high-metastasizing B16 melanoma in mice

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 4, 2011, Pages 339-349

  Skivka, L M ^a   Susak, Yam ^b   Trompak, O O ^c   Kudryavets, Yui ^d   Bezdeneznikh, N ^d   Semesiuk, N ^d   Lykhova, O ^d  

^a TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

^b BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^c NATIONAL UNIVERSITY OF KYIV MOHYLA ACADEMY   (Ukraine)

^d R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

biological properties of tumor cells; high metastatic melanoma B16; low metastatic melanoma B16; NSC 631570; pathogen associated molecules

Indexed keywords

ARGINASE; MICROBIAL PRODUCTS NOT CLASSIFIED ELSEWHERE; NSC 631570; PATHOGEN ASSOCIATED MOLECULE; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UKRAIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; MELANOMA; MELANOMA B16; MONOTHERAPY; MOUSE; NONHUMAN; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BERBERINE ALKALOIDS; CELL DEATH; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PHENANTHRIDINES; RANDOM ALLOCATION; TUMOR CELLS, CULTURED;

EID: 82555194256     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210382470     Document Type: Article

References (39)

1. Lee JT, Herlyn M.. Microenvironmental influences in melanoma progression. J Cell Biochem. 2007 ; 101: 862-872 (Pubitemid 47040868)
2. Villanueva J, Herlyn M.. Melanoma and the tumor microenvironment. Curr Oncol Rep. 2008 ; 10: 439-446
3. Hendrix MJ, Seftor EA, Kirschmann DA, et al. Remodeling of the microenvironment by aggressive melanoma tumor cells. Ann N Y Acad Sci. 2003 ; 995: 151-161 (Pubitemid 36706622)
4. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ.. Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res. 2006 ; 66: 7833-7836 (Pubitemid 44299141)
5. Postovit LM, Margaryan NV, Seftor EA, Hendrix MJ.. Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res. 2008 ; 21: 348-357 (Pubitemid 351678084)
6. Doroshenko YM, Karavay AV, Hodysh YY, et al. The dynamics of concentration of the main fluorescent component of Ukrain in the tissues and blood plasma of rats with W-256 tumor after a single intravenous injection. Drugs Exp Clin Res. 2000 ; 26: 171-177 (Pubitemid 32373342)
7. Ernst E, Schmidt K.. Ukrain-a new cancer cure? A systematic review of randomised clinical trials. BMC Cancer. 2005 ; 5: 1-7
8. Lanvers-Kaminsky C, Nolting DM, Köster J, et al. In-vitro toxicity of Ukrain against human Ewing tumor cell lines. Anticancer Drugs. 2006 ; 17: 1025-1030 (Pubitemid 44454779)
9. Grinevich Y, Shalimov S, Bendyuh G, et al. Effect of Ukrain on the growth and metastasizing of Lewis carcinoma in C57BL/6 mice. Drugs Exp Clin Res. 2005 ; 31: 59-70 (Pubitemid 350056457)
10. Mozhenok TP, Beliaeva TN, Leont'eva EA, Faddeeva MD.. Effect of alkaloid sanguinarine and a pharmaceutical preparation ukrain on modulation of vesicular membrane fusion and actin cytoskeleton of macrophages. Tsitologiia. 2005 ; 47: 860-865
11. Gansauge F, Ramadani M, Schwarz M, Beger HG, Lotspeich E, Poch B.. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer. Hepatogastroenterology. 2007 ; 54: 917-920 (Pubitemid 46903753)
12. Nowicky W.. Clinical testing of Ukrain. Lancet Oncol. 2001 ; 2: 10-10
13. Zemskov VS, Susak YM, Todor IN, et al. Antimetastatic effect of Ukrain and its influence on the oxygen and energy metabolism in mice with melanoma B-16. Exp Oncol. 1996 ; 18: 175-177
14. Zemskov SV, Khranovska NN, Skachkova OV, et al. New dendritic cell based immunotherapy regime for treatment of metastatic melanoma. Ann Oncol. 2008 ; 19: 130-132
15. Hamler F, Hiesmayr W, Korsh OB, Melnyk A.. Ukrain monotherapy in malignant melanoma (case report). Drugs Exp Clin Res. 1996 ; 22: 163-166
16. Mickonas A.. NSC-631570-new drug conception for melanoma treatment. Pigment Cell Melanoma Res. 2009 ; 22: 888-888
17. Hohenwarter O, Strutzenberger K, Katinger H, et al. Selective inhibition of in vitro cell growth by the anti-tumor drug Ukrain. Drugs Exp Clin Res. 1992 ; 18: 1-1
18. Kemény-Beke A, Aradi J, Damjanovich J, et al. Apoptotic response of uveal melanoma cells upon treatment with chelidonine, sanguinarine and chelerythrine. Cancer Lett. 2006 ; 237: 67-75 (Pubitemid 44262314)
19. Hauschild A, Egberts F, Russo P, Kähler KC.. Individualized therapy of disseminated cancer using malignant melanoma as a model. Cancer Metastasis Rev. 2006 ; 25: 253-256 (Pubitemid 43886400)
20. Tormo D, Ferrer A, Bosch P, et al. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res. 2006 ; 66: 5427-5435 (Pubitemid 43844970)
21. Kohlmeyer J, Cron M, Landsberg J, Bald T, et al. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res. 2009 ; 69: 6265-6274
22. Macrophages and dendritic cells. Methods and protocols. Neil ER, ed. New York: Humana Press ; 2009: 368.
23. Kudryavets YuI.. Interferon-alpha enhances development of apoptosis induced by various agents in tumor cells in vitro. Exp Oncol. 2001 ; 23: 267-273
24. Roublevskaia IN, Polevoda BV, Ludlow JW, Haake AR.. Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug Ukrain. Anticancer Res. 2000 ; 20: 3163-3167
25. Habermehl D, Kammerer B, Handrick R, et al. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer. 2006 ; 6: 14-14
26. Ferrer P, Asensi M, Priego S, et al. Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma. J Biol Chem. 2007 ; 282: 2880-2890 (Pubitemid 47086274)
27. Tao J, Li Y, Liu YQ, et al. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors. Br J Dermatol. 2008 ; 158: 88-94 (Pubitemid 350221920)
28. Tao J, Li Y, Liu YQ, et al. Restoration of the expression of transports associated with antigen processing in human malignant melanoma increases tumor-specific immunity. J Invest Dermatol. 2008 ; 128: 1991-1996 (Pubitemid 352001195)
29. Seliger B.. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother. 2008 ; 7: 1719-1726
30. Seliger B, Wollscheid U, Momburg F, et al. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 2001 ; 61: 1095-1099 (Pubitemid 32174430)
31. Akira S, Uematsu S, Takeuchi O.. Pathogen recognition and innate immunity. Cell. 2006 ; 124: 783-801 (Pubitemid 43261452)
32. Lehnardt S, Wennekamp J, Freyer D, et al. TLR2 and Caspase-8 are essential for group B Streptococcus-induced apoptosis in microglia. J Immunol. 2007 ; 179: 6134-6143
33. Yang HZ, Cui B, Liu HZ, et al. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One. 2009 ; 4: e6520 - e6520
34. Hussein MR.. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int J Exp Pathol. 2006 ; 87: 163-176 (Pubitemid 43781682)
35. Jensen TO, Schmidt H, Møller HJ, et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009 ; 27: 3330-3337
36. O'Mahony DS, Pham U, Iyer R, et al. Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages. Int J Med Sci. 2008 ; 5: 1-8
37. Jaboski M.. Ukrain (NSC-631570) influences on bone status: a review. Drugs Exp Clin Res. 2000 ; 26: 317-320
38. Marconi C, Bianchini F, Mannini A, et al. Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells. Clin Exp Metastasis. 2008 ; 25: 225-231
39. Mori M, Gotoh T.. Arginine metabolic enzymes, nitric oxide and infection. J Nutr. 2004 ; 134: 2820S - 2825S; (Pubitemid 39315229)